IntroductionAcute post-operative pain remains a troublesome complication of
cardiothoracic surgeries. Several randomized controlled trials have examined
the efficacy of dexmedetomidine as a single or as an adjuvant agent before,
during and after surgery. However, no evidence-based conclusion has been
reached regarding the advantages of dexmedetomidine over the other
analgesics.ObjectiveTo review the effect of dexmedetomidine on acute post-thoracotomy/sternotomy
pain.MethodsMedline, SCOPUS, Web of Science, and Cochrane databases were used to search
for randomized controlled trials that investigated the analgesia effect of
dexmedetomidine on post-thoracotomy/sternotomy pain in adults' patients. The
outcomes were postoperative pain intensity or incidence, postoperative
analgesia duration, and the number of postoperative analgesic
requirements.ResultsFrom 1789 citations, 12 trials including 804 subjects met the inclusion
criteria. Most studies showed that pain score was significantly lower in the
dexmedetomidine group up to 24 hours after surgery. Two studies reported the
significant lower postoperative analgesia requirements and one study
reported the significant lower incidence of acute pain after surgery in
dexmedetomidine group. Ten studies found that the total consumption of
narcotics was significantly lower in the dexmedetomidine group. The most
reported complications of dexmedetomidine were nausea/vomiting, bradycardia
and hypotension.ConclusionDexmedetomidine can be used as a safe and efficient analgesic agent for
reducing the postoperative pain and analgesic requirements up to 24 hours
after cardiothoracic surgeries. However, further well-designed trials are
needed to find the optimal dosage, route, time, and duration of
dexmedetomidine administration.